贝莱特生物 BLTE
$154.19 +$11.00 (+7.68%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $154.19 0.00%
开盘$144.50
昨收$143.19
当日区间$141.00 – $155.80
成交量174.5K
市值$6.21B
市盈率（TTM）–
股息率–
BLTE 相关新闻
匹配 Belite Bio 或代码 BLTE 的头条新闻，按最新排序。
- Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $234 正面
- Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
- H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245
- H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $245 正面
- Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $220
- CCORF Initiates Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $303
- H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $214
- BofA Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $200
- Belite Bio(BLTE.US) Officer Sells US$12.8 Million in Common Stock
- Belite Bio(BLTE.US) Officer Sells US$19.08 Million in Common Stock
- Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
- Morgan Stanley Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $206 正面
- Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $200
- Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)
- Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)
暂无评论——快来第一个聊聊 BLTE。